

Accepted Manuscript

FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer

Kelly M. Kreitzburg, Samuel C. Fehling, Charles N. Landen, Tracy L. Gamblin, Rebecca B. Vance, Rebecca C. Arend, Ashwini A. Katre, Patsy G. Oliver, Robert C.A.M. van Waardenburg, Ronald D. Alvarez, Karina J. Yoon

PII: S0304-3835(18)30527-5

DOI: [10.1016/j.canlet.2018.08.015](https://doi.org/10.1016/j.canlet.2018.08.015)


Reference: CAN 14029

To appear in: *Cancer Letters*

Received Date: 20 March 2018

Revised Date: 9 August 2018

Accepted Date: 10 August 2018



Please cite this article as: K.M. Kreitzburg, S.C. Fehling, C.N. Landen, T.L. Gamblin, R.B. Vance, R.C. Arend, A.A. Katre, P.G. Oliver, R.C.A.M van Waardenburg, R.D. Alvarez, K.J. Yoon, FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.08.015.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ABSTRACT

Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States. Although most patients respond to frontline therapy, virtually all patients relapse with chemoresistant disease. This study addresses the hypothesis that carboplatin or tamoxifen + FTY720, a sphingosine analogue, will minimize or circumvent drug-resistance in ovarian cancer cells and tumor models.

In vitro data demonstrate that FTY720 sensitized two drug-resistant (A2780.cp20, HeyA8.MDR) and two high-grade serous ovarian cancer cell lines (COV362, CAOV3) to carboplatin, a standard of care for patients with ovarian cancer, and to the selective estrogen receptor modulator tamoxifen. FTY720 + tamoxifen was synergistic *in vitro*, and combinations of FTY720 + carboplatin or + tamoxifen were more effective than each single agent in a patient-derived xenograft model of ovarian carcinoma. FTY720 + tamoxifen arrested tumor growth. FTY720 + carboplatin induced tumor regressions, with tumor volumes reduced by ~86% compared to initial tumor volumes. Anti-tumor efficacy was concomitant with increases in intracellular proapoptotic lipid ceramide. The data suggest that FTY720 + tamoxifen or carboplatin may be effective in treating ovarian tumors.

Download English Version:

<https://daneshyari.com/en/article/8943851>

Download Persian Version:

<https://daneshyari.com/article/8943851>

[Daneshyari.com](https://daneshyari.com)